t
| Date | 26 Sept 2023 |
| Time | 15:47:05 |
| Category | Director/PDMR dealings |
| ID | 7254N |
PDMR Dealings
Oxford, UK - 26 September 2023: Oxford Biomedica plc ("Oxford Biomedica" or " the Company") (LSE:OXB), a quality and innovation-led viral vector CDMO, today announces that Leone Patterson, Non-Executive Director, and Professor Dame Kay Davies, Senior Independent Director, have both purchased ordinary shares in the Company.
The ordinary shares purchased by Leone Patterson were acquired pursuant to the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, where an additional fee of up to £50,000 per annum may be paid to any Non-Executive Director recruited from or based in the United States to reflect market levels of remuneration in the United States for Non-Executive Directors, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition.
The following table sets out the number of shares purchased for each Director and additional information.
|
Name of PDMR |
Number of ordinary shares purchased |
Number of ordinary shares now held |
Total number of ordinary shares held as a percentage of the Company's share capital |
|
Leone Patterson |
6,598 |
12,447 |
0.013% |
|
Kay Davies |
1,000 |
1,000 |
0.001% |
The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR") |
|||||
|
a) |
Name |
Leone Patterson |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Non-Executive Director
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Purchase of shares |
||||
|
c) |
Currency |
GBP - British pound |
||||
|
d) |
Price(s) and volumes(s)
|
|
||||
|
e) |
Aggregated information - Aggregate volume - Aggregated total
|
6,598
£19,167.19 |
||||
|
f) |
Date of the transaction |
2023-09-26; 13:30 |
||||
|
g) |
Place of the transaction |
London Stock Exchange, Main Market (XLON) |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR") |
|||||
|
a) |
Name |
Kay Davies |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Senior Independent Director
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Purchase of shares |
||||
|
c) |
Currency |
GBP - British pound |
||||
|
d) |
Price(s) and volumes(s)
|
|
||||
|
e) |
Aggregated information - Aggregate volume - Aggregated total
|
1,000
£2,910 |
||||
|
f) |
Date of the transaction |
2023-09-26; 12:37 |
||||
|
g) |
Place of the transaction |
London Stock Exchange, Main Market (XLON) |
||||
-Ends-
|
For further information, please contact: |
|
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn and YouTube.